Section Arrow
RGNX.NASDAQ
- REGENXBIO
Quotes are at least 15-min delayed:2026/01/08 06:17 EST
Pre Market
Last
 15.2
-0.04 (-0.26%)
Bid
14.5
Ask
15.24
High 15.24 
Low 15.2 
Volume 12 
Regular Hours (Closed)
Last
 15.24
+1.06 (+7.48%)
Day High 
15.8 
Prev. Close
14.18 
1-M High
15.41 
Volume 
867.29K 
Bid
14.5
Ask
15.24
Day Low
14.38 
Open
14.44 
1-M Low
12.61 
Market Cap 
717.84M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 14.19 
20-SMA 13.84 
50-SMA 12.84 
52-W High 15.41 
52-W Low 5.035 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-3.46/-2.49
Enterprise Value
791.97M
Balance Sheet
Book Value Per Share
3.19
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
83.33M
Operating Revenue Per Share
1.92
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
ASBPAspire Biopharma Holdings Inc.0.1256+0.0206+19.62%-- 
Pre Market 0.1215 -0.0041 -3.26%
ERASErasca5.17+1.54+42.42%-- 
Pre Market 4.52 -0.65 -12.57%
RXRXRecursion Pharmaceuticals4.86+0.31+6.81%-- 
Pre Market 4.77 -0.09 -1.85%
VTYXVentyx Biosciences13.73+3.68+36.62%-- 
Pre Market 13.74 +0.01 +0.07%
GLUEMonte Rosa Therapeutics23.28+7.27+45.41%54.09PE
Pre Market 22.99 -0.29 -1.25%
Industry overview quotes are at least 15 minutes delayed
Business Description
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that the Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.